Cite
The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficileinfection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines
MLA
Mullish, Benjamin H., et al. “The Use of Faecal Microbiota Transplant as Treatment for Recurrent or Refractory Clostridium Difficileinfection and Other Potential Indications: Joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) Guidelines.” Gut, vol. 67, no. 11, Jan. 2018, pp. 1920–41. EBSCOhost, https://doi.org/10.1136/gutjnl-2018-316818.
APA
Mullish, B. H., Quraishi, M. N., Segal, J. P., McCune, V. L., Baxter, M., Marsden, G. L., Moore, D. J., Colville, A., Bhala, N., Iqbal, T. H., Settle, C., Kontkowski, G., Hart, A. L., Hawkey, P. M., Goldenberg, S. D., & Williams, H. R. T. (2018). The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficileinfection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. Gut, 67(11), 1920–1941. https://doi.org/10.1136/gutjnl-2018-316818
Chicago
Mullish, Benjamin H, Mohammed Nabil Quraishi, Jonathan P Segal, Victoria L McCune, Melissa Baxter, Gemma L Marsden, David J Moore, et al. 2018. “The Use of Faecal Microbiota Transplant as Treatment for Recurrent or Refractory Clostridium Difficileinfection and Other Potential Indications: Joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) Guidelines.” Gut 67 (11): 1920–41. doi:10.1136/gutjnl-2018-316818.